Bismacine
Patent medicine
From Wikipedia, the free encyclopedia
Bismacine, also known as Chromacine, is a substance manufactured by American Biologics Corporation and marketed as a purported alternative treatment for Lyme disease. Bismacine is based on bismuth compounds, and two deaths have followed the use of intravenous bismacine to treat Lyme disease.[1] In 2006, the U.S. Food and Drug Administration warned consumers not to use bismacine, noting that it is ineffective and dangerous.[2]
